首页> 外文期刊>Forum of nutrition >Functionality of Probiotics-Potential for Product Development
【24h】

Functionality of Probiotics-Potential for Product Development

机译:益生菌的功能-产品开发的潜力

获取原文
获取原文并翻译 | 示例
       

摘要

It is becoming increasingly accepted by consumers that live lactic acid bacteria do exert health benefits when eaten. In addition, it is also becoming recognised that not all probiotic bacteria are equal. It is now no longer just a question of providing sufficient numbers of viable bacteria in a product; industry must also provide proof of efficacy for each strain. In the early 1990s, Fonterra embarked on a programme to develop proprietary probiotic strains, and as a result, commercialised two strains, Bifidobacterium lactis HN019 and Lactobacillus rhamnosus HN001. Over the past decade, Fonterra has developed a significant body of peer-reviewed published reports around these strains, including studies showing safety in animal and human trials, protection against pathogens such as Salmonella typhimurium and Escherichia coli O157:H7, modulation of human and animal immune markers at realistic dose rates, and efficacy in human clinical trials. Based on this work, HN019 and HN001 have been applied to several functional foods both by Fonterra (under the DR10 and DR20 brands, respectively) and by third parties (e.g. under the HOWARU brand by Danisco). While the 'gold standard' of proof of efficacy is a phase III clinical trial, ethical considerations aswell as expense preclude the use of clinical trials as screening tools for pro-biotics. Therefore, biomarkers have to be employed to identify strains with probiotic utility, and to define the different positive health benefits of existing probiotic strains. However, as the mechanisms by which most probiotic bacteria exert their health benefits remain unclear, the question of which biomarkers accurately reflect efficacy in vivo remains unresolved. With recent technological advances, and the shift towardprobiotics targeted to specific conditions, researchers are beginning to tease out how probiotic bacteria work, and it is this knowledge that will inform biomarker development and improve the ability to offer the market safe and effective probiotic functional foods.
机译:食用乳酸菌确实对食用有益健康,这已被消费者越来越接受。此外,人们也认识到并非所有益生菌都是平等的。现在不再仅仅是在产品中提供足够数量的活细菌的问题;工业界还必须提供每种菌株功效的证明。在1990年代初期,恒天然开始了一项计划,以开发专有的益生菌菌株,结果将两种菌株乳酸双歧杆菌HN019和鼠李糖乳杆菌HN001商业化。在过去的十年中,恒天然围绕这些菌株开发了许多经过同行评审的报告,包括表明在动物和人体试验中的安全性,对鼠伤寒沙门氏菌和大肠杆菌O157:H7等病原体的保护,对人类和动物的调节的研究现实剂量率的免疫标记,以及在人类临床试验中的功效。基于这项工作,Fonterra(分别以DR10和DR20品牌)和第三方(例如Danisco以HOWARU品牌)已将HN019和HN001应用于几种功能性食品。疗效证明的“黄金标准”是一项III期临床试验,但出于伦理考虑以及费用的考虑,排除了将临床试验用作益生菌筛选工具的可能性。因此,必须使用生物标志物来鉴定具有益生菌效用的菌株,并定义现有益生菌菌株的不同的积极健康益处。然而,由于大多数益生菌发挥健康益处的机制尚不清楚,因此哪些生物标记物能准确反映体内功效的问题仍未解决。随着最新技术的发展,以及针对特定条件的益生菌的转移,研究人员开始弄清益生菌的工作原理,正是这些知识将有助于生物标记物的开发,并提高向市场提供安全有效的益生菌功能食品的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号